Autoimmune Diseases Causing Tinnitus and Sensorineural Hearing Loss
The primary autoimmune diseases that cause tinnitus and sensorineural hearing loss include rheumatoid arthritis, systemic lupus erythematosus, granulomatosis with polyangiitis (Wegener's), Cogan's syndrome, relapsing polychondritis, polyarteritis nodosa, systemic sclerosis, IgG4-related disease, and antiphospholipid syndrome.
Key Autoimmune Conditions
Most Common Systemic Autoimmune Diseases
Rheumatoid arthritis is a well-documented cause of autoimmune inner ear disease (AIED), presenting with sudden-onset bilateral sensorineural hearing loss and tinnitus 1. The condition responds well to steroids and disease-modifying agents like leflunomide, with potential for complete tinnitus resolution and significant hearing improvement when treated promptly 1.
Systemic lupus erythematosus frequently involves the inner ear as part of systemic autoimmune manifestations 2, 3. Antiphospholipid antibodies are particularly important, with a 29% prevalence in AIED patients 3. Lupus anticoagulant is the most frequently detected antibody, followed by anticardiolipin and anti-beta2 glycoprotein 3.
Granulomatosis with polyangiitis (Wegener's) and Cogan's syndrome are specifically mentioned as systemic diseases where AIED can occur 3. These conditions require aggressive immunosuppression beyond standard corticosteroid therapy.
Additional Autoimmune Conditions
Relapsing polychondritis causes immune-mediated damage to cartilaginous structures including the inner ear, leading to progressive sensorineural hearing loss, vestibular symptoms, and tinnitus 4, 3.
Polyarteritis nodosa involves vasculitic damage to the inner ear vasculature 2, 3.
Systemic sclerosis shows a 42.9% prevalence of sensorineural hearing loss in affected patients, significantly higher than controls 5. Tinnitus occurs in 11.4% of systemic sclerosis patients, with vestibular dysfunction in 60% 5.
IgG4-related disease represents a newer recognized cause of AIED, requiring specific immunosuppressive strategies 4.
Clinical Presentation Patterns
Hearing Loss Characteristics
The hearing loss in autoimmune disease is typically:
- Bilateral and asymmetric in most cases 2, 6
- Progressive over weeks to months rather than sudden 3, 6
- Fluctuating in nature, which distinguishes it from other causes 6
- Rapidly progressive in primary AIED 3
Associated Symptoms
Vestibular symptoms occur in up to 50% of patients with autoimmune SNHL 6. These include vertigo and dizziness that often mimic Menière's disease 2.
Tinnitus is present in up to 50% of patients with autoimmune SNHL 6. The tinnitus can be bilateral and may resolve completely with appropriate immunosuppressive treatment 1.
Aural fullness accompanies the hearing loss and tinnitus in up to 50% of cases 6.
Pathophysiologic Mechanisms
The underlying mechanisms involve:
- Molecular mimicry where antibodies cross-react with inner ear antigens 4
- Bystander effect causing collateral immune damage 4
- Specific autoantibodies against heat shock protein 70 (HSP70) playing a role in cochlear damage 4
- Vasculitic damage to inner ear microvasculature in conditions like polyarteritis nodosa
Diagnostic Approach
Critical Pitfall to Avoid
Do not rely on specific autoantibody testing for diagnosis of AIED - there is no definitive test capable of identifying the specific inner ear antigen 3, 6. Diagnosis relies on clinical suspicion and responsiveness to corticosteroids 6.
Essential Workup
When evaluating suspected autoimmune SNHL:
- Obtain pure tone audiometry immediately to document the pattern and severity 6
- Order MRI of internal auditory canals to exclude vestibular schwannoma 7
- Perform limited laboratory workup including antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta2 glycoprotein), ANA, RF, anti-CCP, ANCA, and inflammatory markers 3, 6
- Look for systemic autoimmune features on history and physical examination - joint symptoms, rashes, sicca symptoms, cartilage inflammation 4, 2
Antiphospholipid Antibodies Deserve Special Attention
Screen for antiphospholipid antibodies in all AIED patients given the 29% prevalence 3. Detection of these antibodies requires specific therapeutic management to prevent audiometric deterioration 3. Double positivity occurs in 25% of positive patients 3.
Treatment Implications
Glucocorticoids are first-line therapy, effective in 70% of cases 4. Early intervention is crucial - the prognosis for hearing improvement depends on prompt treatment initiation 4, 1.
For steroid-resistant or partial responders:
- Add methotrexate as a steroid-sparing agent 4
- Consider biologic therapies including anti-TNF and IL-6 receptor antagonists for refractory cases 4
- Tailor treatment to the underlying systemic disease - for example, leflunomide in rheumatoid arthritis 1
The response to corticosteroids is diagnostic - near-complete hearing restoration can occur with appropriate treatment 2. This good response to immunosuppression distinguishes autoimmune SNHL from other causes 2.
Prognosis
Only 25% of patients with antiphospholipid antibody-associated AIED experience audiometric improvement during disease course 3, emphasizing the importance of early aggressive treatment and appropriate anticoagulation when indicated.